Ipamorelin

Description

Ipamorelin is a highly regarded selective GH secretagogue pentapeptide known for its role as a ghrelin receptor agonist. This unique compound offers similar potency in stimulation of growth hormone (GH) secretion when compared to GHRP-6, while exhibiting significantly reduced appetite-stimulating effects. One of the most notable advantages of Ipamorelin is its ability to induce GH release without significantly increasing levels of cortisol, acetylcholine, prolactin, or aldosterone, distinguishing it as one of the most effective and well-tolerated GH secretagogues available.

Dosage

The recommended dosage of Ipamorelin is a minimum of 200 mcg administered once daily, five days a week. It is crucial to adhere to this dosage for optimal results.

Combination Therapy

For enhanced results, it is suggested to use Ipamorelin in combination with CJC-1295 DAC. This combination therapy exploits their complementary mechanisms of action, producing a synergistic effect that can yield up to five times the benefits compared to using either CJC-1295 or Ipamorelin alone. This strategy maximizes the release of growth hormone by targeting both the GHRH-R and ghrelin-R receptors, thus improving overall efficacy.

Regulatory Note

It is important to note that due to regulatory and licensing constraints, we are unable to provide any advice or guidance on how to use or conduct research with these products. Always consult with a healthcare professional or a qualified expert before initiating any treatment or research involving peptides like Ipamorelin.

1. Andersen, N. B., et al. “Ipamorelin, a New Growth-Hormone-Releasing Peptide, Induces Longitudinal Bone Growth in Rats.” Growth Hormone & IGF Research, vol. 9, no. 2, 1999, pp. 106-113. Link

2. Raun, K., et al. “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology, vol. 139, no. 5, 1998, pp. 552-561. Link

3. Ghigo, E., et al. “Ghrelin and the Growth Hormone Secretagogue Receptor in Growth and Development.” International Journal of Obesity, vol. 27, 2003, pp. S23–S27. Link

4. Teichman, S. L., et al. “Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults.” Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 3, 2006, pp. 799-805. Link

5. Bailey, A. R., et al. “Coadministration of the Human Growth Hormone Releaser CJC-1295 and the Antiresorptive Drug Alendronate Affects Bone Shape and Turnover in Ovariectomized Rats.” Journal of Bone and Mineral Research, vol. 26, no. 5, 2011, pp. 1125-1138. Link